country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-184662

Copy Link Print Information

Ferroptosis inducer-17

Ferroptosis inducer-17 is a ferroptosis inducer that downregulates GPX4 and activates the CTSB and cGAS-STING pathways. Ferroptosis inducer-17 exhibits cytotoxicity against cancer cells but low toxicity toward normal cells. Ferroptosis inducer-17 accumulates in mitochondria and lysosomes, thereby inducing ROS production, lipid peroxidation, mitochondrial membrane depolarization, lysosomal iron accumulation, increased membrane permeability, and enhanced oxidative stress. Ferroptosis inducer-17 inhibits tumor growth in cisplatin-resistant xenograft models. Ferroptosis inducer-17 can be used for cancer-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₃₇H₄₁N₃O₇Zr
Molecular Weight:730.96

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Ferroptosis inducer-17 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

GPX4	Cathepsin B

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen :

GPX1
GPX4

Alle Cathepsin Isoform-spezifische Produkte anzeigen :

In Vitro

Ferroptosis inducer-17 (compound 1t) (range of concentrations; 48 h) potently inhibits proliferation of Hep G2, Hep G2/DDP, SW620/DDP, and HeLa S3 cancer cells with IC₅₀ values of 3.9 μM, 2.3 μM, 13.9 μM, and 51.8 μM respectively, while sparing normal LO2 liver cells^[1].
Ferroptosis inducer-17 (compound 1t) (4 μM; 24 h, 48 h) potently inhibits migration of Hep G2/DDP cells after 24 h and 48 h of incubation^[1].
Ferroptosis inducer-17 (compound 1t) (4 μM; 0.1-48 h) accumulates continuously in Hep G2/DDP cells over 48 h, reaching a maximum Zr content of 22.50 ng^[1].
Ferroptosis inducer-17 (4 μM; 24 h) preferentially localizes to mitochondria and lysosomes in Hep G2/DDP cells after 24 h of incubation^[1].
Ferroptosis inducer-17 (4 μM; 24 h) induces ferroptosis as the predominant mode of cell death in Hep G2/DDP cells, with a minor contribution from apoptosis^[1].
Ferroptosis inducer-17 (4 μM) induces G1-phase cell cycle arrest in Hep G2/DDP cells^[1].
Ferroptosis inducer-17 (4 μM) disrupts redox homeostasis in Hep G2/DDP cells and promotes membrane damage associated with lipid peroxidation; also increases ROS levels in Hep G2/DDP cells; causes mitochondrial membrane depolarization in Hep G2/DDP cells^[1].
Ferroptosis inducer-17 (4 μM; 12 h) downregulates GPX4 protein expression in Hep G2/DDP cells^[1].
Ferroptosis inducer-17 (4 μM; 24 h) increases lysosomal iron^II levels and lysosomal pH in Hep G2/DDP cells^[1].
Ferroptosis inducer-17 (4 μM; 24 h) upregulates NCOA4 and SLC7A11 protein expression in Hep G2/DDP cells^[1].
Ferroptosis inducer-17 (4 μM; 24 h) modulates the expression of IFN-α, IFN-β, IFN-γ, IL-6, cGAS, and STING in Hep G2/DDP cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

Hep G2/DDP (cisplatin-resistant hepatocellular carcinoma)
Concentration:

4 μM
Incubation Time:

24 h, 48 h
Result:

Markedly inhibited Hep G2/DDP cell migration, reducing wound closure rates from 26.42% (control) to 1.73% at 24 h.
Markedly inhibited Hep G2/DDP cell migration, reducing wound closure rates from 40.88% (control) to 7.87% at 48 h.

Cell Viability Assay^[1]

Cell Line:

Hep G2/DDP (cisplatin-resistant hepatocellular carcinoma)
Concentration:

4 μM; 10 μM (Ferrostatin-1, 3-MA), 20 μM (Z-VAD-FMK)
Incubation Time:

24 h (Ferroptosis inducer-17); 1 h (inhibitors pretreatment)
Result:

Only Ferrostatin-1 (HY-100579) (ferroptosis inhibitor) and Z-VAD-FMK (HY-16658B) (apoptosis inhibitor) substantially rescued cell viability, with Ferrostatin-1 showing the most significant rescue effect.

Western Blot Analysis^[1]

Cell Line:

Hep G2/DDP (cisplatin-resistant hepatocellular carcinoma)
Concentration:

4 μM
Incubation Time:

12 h
Result:

Markedly reduced GPX4 protein expression levels compared to untreated control cells.

Western Blot Analysis^[1]

Cell Line:

Hep G2/DDP (cisplatin-resistant hepatocellular carcinoma)
Concentration:

4 μM
Incubation Time:

24 h
Result:

Markedly increased NCOA4 protein expression levels compared to untreated control cells.
Markedly increased SLC7A11 protein expression levels compared to untreated control cells.

Real Time qPCR^[1]

Cell Line:

Hep G2/DDP (cisplatin-resistant hepatocellular carcinoma)
Concentration:

4 μM
Incubation Time:

24 h
Result:

Modulated the expression of IFN-α, IFN-β, IFN-γ, IL-6, cGAS, and STING.

In Vivo

Ferroptosis inducer-17 (compound 1t) (2.9 mg/kg; i.v.; single dose) significantly suppresses tumor growth in cisplatin-resistant hepatocellular carcinoma orthotopic xenografts with minimal systemic toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/SCID (male, 5-6 weeks old)^[1]
Dosage:

2.9 mg/kg
Administration:

i.v.; single dose
Result:

Significantly suppressed tumor growth in the cisplatin-resistant Hep G2/DDP orthotopic xenograft model.
Showed minimal systemic toxicity.

Related Protocols :

Chemical Information

Molecular Weight 730.96
Formel C₃₇H₄₁N₃O₇Zr
SMILES

CC1=CC(C(C)(C)C)=C2O[Zr]34(OC5=O)(OC(C6=CC(O)=CC5=N6)=O)OC7=C(C(C)(C)C)C=C(C)C=C7C[N]3(CC8=CC=CC=[N]84)CC2=C1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Zhao T, et al. GPX4-Targeting Phenolato Zr Complexes Induce Ferroptosis and Lysosome-Dependent Cell Death for Immunotherapy of Chemoresistant Cancer. Journal of medicinal chemistry. 2026 Jun 25. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ferroptosis inducer-17

Alle Glutathione Peroxidase Isoform-spezifische Produkte anzeigen

Alle Cathepsin Isoform-spezifische Produkte anzeigen